home · filing · 0001193125-24-256699
8-K filed November 13, 2024, 6:59 PM ET
ticker ORGO
CIK 0001661181
other material
confidence high
sentiment positive
materiality 0.80
Organogenesis raises $130M convertible preferred, repurchases 7.4M shares, appoints Avista director
Organogenesis Holdings Inc.
Sold 130,000 shares of Series A Convertible Preferred Stock at $1,000/share for gross proceeds of $130M.
Net proceeds used for strategic growth, debt repayment, and repurchase of 7.4M common shares from directors at $3.1597/share (~$23.5M).
Preferred pays 8% annual dividend, compounded quarterly, payable in cash or PIK; conversion price initially $3.7917 (20% premium).
Company expects to prepay ~$62.5M term loan principal and interest on Nov 13, 2024, using offering proceeds.
Appointed Garrett Lustig (Avista Principal) to Board, increasing board size to twelve.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-11-12
Filed November 13, 2024, 6:59 PM ET
On November 12, 2024, the Board appointed Garrett Lustig to the Board, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Garrett Lustig was appointed as Director at Organogenesis Holdings Inc..
Action appointed
Role Director
Exact text from the filing
On November 12, 2024, the Board appointed Garrett Lustig to the Board, effective immediately.
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-24-256699
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.